GeneQuine Biotherapeutics develops gene therapies aimed at musculoskeletal disorders, with a platform designed to produce therapeutic proteins locally in target tissues. Its lead candidate, GQ-303, is being developed as a locally administered treatment for osteoarthritis and has shown potential as symptomatic and disease‑modifying therapy in several animal models. The company plans to advance GQ-303 to a Phase 1 clinical trial, develop gene therapies for intervertebral disc degeneration, expand its gene therapy vector platform, and grow operations. GeneQuine raised a total of €9.05m in the described financing (see deal details). The company previously had a program acquired by Flexion Therapeutics in 2017 that is currently in clinical Phase 1 testing. GeneQuine is headquartered in Hamburg and has sites in Luckenwalde (greater Berlin area), Germany, and Liège, Belgium. GeneQuine Biotherapeutics develops gene therapy treatments for osteoarthritis, initially focusing on veterinary applications. Its lead product is GQ-201 for osteoarthritis in horses, with a second candidate aimed at dogs. The company's long-term goal is to develop a gene therapeutic drug for osteoarthritis in humans. The underlying gene therapy technology was co-developed by CEO and co-founder Kilian Guse at Dr. Brendan Lee’s research group at Baylor College of Medicine and has shown efficacy in an osteoarthritis mouse model. GeneQuine holds a worldwide, exclusive license for the technology. The company will use new funding to demonstrate proof-of-concept of GQ-201 in a horse osteoarthritis model.

Total raised

$11M

Funding rounds

3

Latest round

Series A

Latest activity

Feb 2021